CONTINUE TO SITE
OR WAIT 15 SECS
Bora Health, subsidiary of SunWay Biotech which focuses on pharmaceutical distribution and sales in Taiwan, ha
AstraZeneca has announced $50 billion of investment in the United States by 2030, building on America’s
Japan-based Astellas Pharma Inc. has agreed on a Memorandum of Understanding (MoU) with the Korea Institu
Alloy Therapeutics Co. has announced the signing of a Memorandum of Understanding (MoU) with the Kansai Startu
Australia-based contract development and manufacturing organisations Viral Vector Manufacturing Facility
US-headquartered NKGen Biotech, Inc. a clinical-stage biotechnology company focused on the development an
DeepQure has announced that South Korea's Ministry of Food and Drug Safety (MFDS) has approved a clinical tria
Inocras Inc., a global leader in whole-genome sequencing (WGS) and bioinformatics, has announced the signing o
CorestemChemon, a leading GLP-certified preclinical CRO based in South Korea, has entered into a strategi
WuXi Biologics, a leading global Contract Research, Development, and Manufacturing Organisation (CRDMO) in Chi
Medical Advances Soar With APAC’S CLINICAL TRIAL GROWTH
It’s a truth universally acknowledged that Asia-Pacific is a hotbed for clinical trials, with multiple reports confirming that it is the only region in the world to have seen a consistent surge in clinical trial activity. The Asia Pacific clinical trials market generated a revenue of $15.91 billion in 2023 and is expected to reach a projected revenue of $25.99 billion by 2030 at a compound annual growth rate of 7.3 per cent, according to the Grand View Research report. Between 2020 and 2025, China, India, Australia, Japan, South Korea, and Singapore emerged as key pillars of Asia-Pacific’s growing clinical trial ecosystem. Together, these six countries accounted for nearly 40,000 trials (39,843 in total). We take a close look at each country’s clinical trial landscape, examining who is leading in which phases, how domestic players compare to multinational sponsors, and which therapeutic areas are seeing the most activity. We also explore the challenges of running trials across such a diverse region.
13th Tumor Models Boston Summit 2025
Hanson Wade
info@hansonwade.com https://tumor-models.com/Boston
6th Commercializing Flow Chemistry Summit 2025
Hanson Wade
info@hansonwade.com https://commercializing-flow-chemistry.com/Boston
8th International Neoantigen Summit 2025
Hanson Wade
info@hansonwade.com https://hansonwade.com/rna-therapy-conferences/Amsterdam
